elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q39380445-0812743E-E0BF-47EB-A15A-5A4F698CF64A
Q39380445-0812743E-E0BF-47EB-A15A-5A4F698CF64A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39380445-0812743E-E0BF-47EB-A15A-5A4F698CF64A
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
P2860
Q39380445-0812743E-E0BF-47EB-A15A-5A4F698CF64A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39380445-0812743E-E0BF-47EB-A15A-5A4F698CF64A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f6776c5f2ba9c0dc9b1604f674ff56fe0f73e500
P2860
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).